ArticleFrontiers in radiology2026
Longitudinal deep learning-based segmentation of multiple sclerosis lesions in a local clinical cohort.
Article in Frontiers in radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Automated monitoring of multiple sclerosis (MS) lesion progression remains challenging in clinical practice. This study evaluates LongiSeg, a longitudinal deep learning architecture, on heterogeneous clinical data to assess its practical value for routine MS radiological monitoring and extends its use for new lesion detection. Methods: We trained LongiSeg on 470 patients from a diverse clinical cohort acquired across 15 scanner types (both 1.5T and 3T) with mixed 2D/3D T2w FLAIR sequences. We trained and evaluated models for both cross-sectional lesion segmentation and new lesion detection. Performance was compared against a single-timepoint nnU-Net on a cross-sectional test cohort consisting of 67 patients as well as 22 patients presenting with new lesions. Results: LongiSeg achieved superior cross-sectional segmentation performance compared to single-timepoint nnU-Net on the clinical test set ( Conclusion: LongiSeg demonstrated moderate improvements in cross-sectional MS lesion segmentation. However, the added complexity of processing longitudinal scans may not be justified by these modest gains. For new lesion segmentation, performance was low, especially in cases with few lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.